OPZELURA
Google image searchProduct monograph
Active ingredient
ruxolitinib (ruxolitinib phosphate), 1.5 %/W/W
DIN: 02552434
Dosage form(s): CREAM
Route(s) of administration: TOPICAL
Schedule: Prescription
Company: INCYTE CORPORATION
Date: 28-NOV-2024
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01EJ — Janus-associated kinase (JAK) inhibitors (ATC, ATC/DDD)
- L01EJ01 — RUXOLITINIB (ATC/DDD)
Reference brand drug: Jakavi
